\BOOKMARK [0][-]{section*.4}{Acronyms}{}% 1
\BOOKMARK [0][-]{chapter.1}{Introduction and Literature Review}{}% 2
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 3
\BOOKMARK [2][-]{subsection.1.1.1}{Cancer is a Global Health Issue}{section.1.1}% 4
\BOOKMARK [3][-]{subsubsection.1.1.1.1}{The Genetics and Molecular Biology of Cancers}{subsection.1.1.1}% 5
\BOOKMARK [2][-]{subsection.1.1.2}{The Genomics Revolution in Cancer Research}{section.1.1}% 6
\BOOKMARK [3][-]{subsubsection.1.1.2.1}{High-Throughput Technologies}{subsection.1.1.2}% 7
\BOOKMARK [3][-]{subsubsection.1.1.2.2}{Bioinformatics and Genomic Data}{subsection.1.1.2}% 8
\BOOKMARK [2][-]{subsection.1.1.3}{Genomics Projects}{section.1.1}% 9
\BOOKMARK [3][-]{subsubsection.1.1.3.1}{The Cancer Genome Project}{subsection.1.1.3}% 10
\BOOKMARK [3][-]{subsubsection.1.1.3.2}{The Cancer Genome Atlas Project}{subsection.1.1.3}% 11
\BOOKMARK [2][-]{subsection.1.1.4}{Genomic Cancer Medicine}{section.1.1}% 12
\BOOKMARK [3][-]{subsubsection.1.1.4.1}{Cancer Genes and Driver Mutations}{subsection.1.1.4}% 13
\BOOKMARK [3][-]{subsubsection.1.1.4.2}{Precision Cancer Medicine}{subsection.1.1.4}% 14
\BOOKMARK [3][-]{subsubsection.1.1.4.3}{Molecular Diagnostics and Pan-Cancer Medicine}{subsection.1.1.4}% 15
\BOOKMARK [3][-]{subsubsection.1.1.4.4}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.4}% 16
\BOOKMARK [2][-]{subsection.1.1.5}{Systems and Network Biology}{section.1.1}% 17
\BOOKMARK [1][-]{section.1.2}{Synthetic Lethal Cancer Medicine}{chapter.1}% 18
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 19
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 20
\BOOKMARK [2][-]{subsection.1.2.3}{Synthetic Lethality in Model Systems}{section.1.2}% 21
\BOOKMARK [3][-]{subsubsection.1.2.3.1}{Synthetic Lethal Pathways and Networks}{subsection.1.2.3}% 22
\BOOKMARK [3][-]{subsubsection.1.2.3.2}{Evolution of Synthetic Lethality}{subsection.1.2.3}% 23
\BOOKMARK [2][-]{subsection.1.2.4}{Synthetic Lethality in Cancer}{section.1.2}% 24
\BOOKMARK [2][-]{subsection.1.2.5}{Clinical Impact of Synthetic Lethality in Cancer}{section.1.2}% 25
\BOOKMARK [2][-]{subsection.1.2.6}{High-throughput Screening for Synthetic Lethality}{section.1.2}% 26
\BOOKMARK [3][-]{subsubsection.1.2.6.1}{Synthetic Lethal Screens}{subsection.1.2.6}% 27
\BOOKMARK [2][-]{subsection.1.2.7}{Computational Prediction of Synthetic Lethality}{section.1.2}% 28
\BOOKMARK [3][-]{subsubsection.1.2.7.1}{Bioinformatics Approaches to Genetic Interactions}{subsection.1.2.7}% 29
\BOOKMARK [3][-]{subsubsection.1.2.7.2}{Comparative Genomics}{subsection.1.2.7}% 30
\BOOKMARK [3][-]{subsubsection.1.2.7.3}{Analysis and Modelling of Protein Data}{subsection.1.2.7}% 31
\BOOKMARK [3][-]{subsubsection.1.2.7.4}{Differential Gene Expression}{subsection.1.2.7}% 32
\BOOKMARK [3][-]{subsubsection.1.2.7.5}{Data Mining and Machine Learning}{subsection.1.2.7}% 33
\BOOKMARK [3][-]{subsubsection.1.2.7.6}{Mutual Exclusivity and Bimodality}{subsection.1.2.7}% 34
\BOOKMARK [3][-]{subsubsection.1.2.7.7}{Rationale for Further Development}{subsection.1.2.7}% 35
\BOOKMARK [1][-]{section.1.3}{E-cadherin as a Synthetic Lethal Target}{chapter.1}% 36
\BOOKMARK [2][-]{subsection.1.3.1}{The CDH1 gene and its Biological Functions}{section.1.3}% 37
\BOOKMARK [2][-]{subsection.1.3.2}{Hereditary Diffuse Gastric \(and Lobular Breast\) Cancer}{section.1.3}% 38
\BOOKMARK [2][-]{subsection.1.3.3}{Cell Line Models of CDH1 Null Mutations}{section.1.3}% 39
\BOOKMARK [1][-]{section.1.4}{Summary and Research Direction of Thesis}{chapter.1}% 40
\BOOKMARK [2][-]{subsection.1.4.1}{Thesis Aims}{section.1.4}% 41
\BOOKMARK [0][-]{chapter.2}{Methods and Resources}{}% 42
\BOOKMARK [1][-]{section.2.1}{Bioinformatics Resources for Genomics Research}{chapter.2}% 43
\BOOKMARK [2][-]{subsection.2.1.1}{Public Data and Software Packages}{section.2.1}% 44
\BOOKMARK [3][-]{subsubsection.2.1.1.1}{Cancer Genome Atlas Data}{subsection.2.1.1}% 45
\BOOKMARK [3][-]{subsubsection.2.1.1.2}{Reactome and Annotation Data}{subsection.2.1.1}% 46
\BOOKMARK [1][-]{section.2.2}{Data Handling}{chapter.2}% 47
\BOOKMARK [2][-]{subsection.2.2.1}{Normalisation}{section.2.2}% 48
\BOOKMARK [2][-]{subsection.2.2.2}{Sample Triage}{section.2.2}% 49
\BOOKMARK [2][-]{subsection.2.2.3}{Metagenes and the Singular Value Decomposition}{section.2.2}% 50
\BOOKMARK [2][-]{subsection.2.2.4}{Candidate Triage and Integration with Screen Data}{section.2.2}% 51
\BOOKMARK [1][-]{section.2.3}{Techniques}{chapter.2}% 52
\BOOKMARK [2][-]{subsection.2.3.1}{Statistical Procedures and Tests}{section.2.3}% 53
\BOOKMARK [2][-]{subsection.2.3.2}{Gene Set Over-representation Analysis}{section.2.3}% 54
\BOOKMARK [2][-]{subsection.2.3.3}{Clustering}{section.2.3}% 55
\BOOKMARK [2][-]{subsection.2.3.4}{Heatmap}{section.2.3}% 56
\BOOKMARK [2][-]{subsection.2.3.5}{Modelling and Simulations}{section.2.3}% 57
\BOOKMARK [3][-]{subsubsection.2.3.5.1}{Receiver Operating Characteristic Curves}{subsection.2.3.5}% 58
\BOOKMARK [2][-]{subsection.2.3.6}{Resampling Analysis}{section.2.3}% 59
\BOOKMARK [1][-]{section.2.4}{Pathway Structure Methods}{chapter.2}% 60
\BOOKMARK [2][-]{subsection.2.4.1}{Network and Graph Analysis}{section.2.4}% 61
\BOOKMARK [2][-]{subsection.2.4.2}{Sourcing Graph Structure Data}{section.2.4}% 62
\BOOKMARK [2][-]{subsection.2.4.3}{Constructing Pathway Subgraphs}{section.2.4}% 63
\BOOKMARK [2][-]{subsection.2.4.4}{Network Analysis Metrics}{section.2.4}% 64
\BOOKMARK [1][-]{section.2.5}{Implementation}{chapter.2}% 65
\BOOKMARK [2][-]{subsection.2.5.1}{Computational Resources and Linux Utilities}{section.2.5}% 66
\BOOKMARK [2][-]{subsection.2.5.2}{R Language and Packages}{section.2.5}% 67
\BOOKMARK [2][-]{subsection.2.5.3}{High Performance and Parallel Computing}{section.2.5}% 68
\BOOKMARK [0][-]{chapter.3}{Methods Developed During Thesis}{}% 69
\BOOKMARK [1][-]{section.3.1}{A Synthetic Lethal Detection Methodology}{chapter.3}% 70
\BOOKMARK [1][-]{section.3.2}{Synthetic Lethal Simulation and Modelling}{chapter.3}% 71
\BOOKMARK [2][-]{subsection.3.2.1}{A Model of Synthetic Lethality in Expression Data}{section.3.2}% 72
\BOOKMARK [2][-]{subsection.3.2.2}{Simulation Procedure}{section.3.2}% 73
\BOOKMARK [1][-]{section.3.3}{Detecting Simulated Synthetic Lethal Partners}{chapter.3}% 74
\BOOKMARK [2][-]{subsection.3.3.1}{Binomial Simulation of Synthetic Lethality}{section.3.3}% 75
\BOOKMARK [2][-]{subsection.3.3.2}{Multivariate Normal Simulation of Synthetic Lethality}{section.3.3}% 76
\BOOKMARK [3][-]{subsubsection.3.3.2.1}{Multivariate Normal Simulation with Correlated Genes}{subsection.3.3.2}% 77
\BOOKMARK [3][-]{subsubsection.3.3.2.2}{Specificity with Query-Correlated Pathways}{subsection.3.3.2}% 78
\BOOKMARK [1][-]{section.3.4}{Graph Structure Methods}{chapter.3}% 79
\BOOKMARK [2][-]{subsection.3.4.1}{Upstream and Downstream Gene Detection}{section.3.4}% 80
\BOOKMARK [3][-]{subsubsection.3.4.1.1}{Permutation Analysis for Statistical Significance}{subsection.3.4.1}% 81
\BOOKMARK [2][-]{subsection.3.4.2}{Simulating Gene Expression from Graph Structures}{section.3.4}% 82
\BOOKMARK [1][-]{section.3.5}{Customised Functions and Packages Developed}{chapter.3}% 83
\BOOKMARK [2][-]{subsection.3.5.1}{Synthetic Lethal Interaction Prediction Tool}{section.3.5}% 84
\BOOKMARK [2][-]{subsection.3.5.2}{Data Visualisation}{section.3.5}% 85
\BOOKMARK [2][-]{subsection.3.5.3}{Extensions to the iGraph Package}{section.3.5}% 86
\BOOKMARK [3][-]{subsubsection.3.5.3.1}{Sampling Simulated Data from Graph Structures}{subsection.3.5.3}% 87
\BOOKMARK [3][-]{subsubsection.3.5.3.2}{Plotting Directed Graph Structures}{subsection.3.5.3}% 88
\BOOKMARK [3][-]{subsubsection.3.5.3.3}{Computing Information Centrality}{subsection.3.5.3}% 89
\BOOKMARK [3][-]{subsubsection.3.5.3.4}{Testing Pathway Structure with Permutation Testing}{subsection.3.5.3}% 90
\BOOKMARK [3][-]{subsubsection.3.5.3.5}{Metapackage to Install iGraph Functions}{subsection.3.5.3}% 91
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 92
\BOOKMARK [1][-]{section.4.1}{Synthetic Lethal Genes in Breast Cancer}{chapter.4}% 93
\BOOKMARK [2][-]{subsection.4.1.1}{Synthetic Lethal Pathways in Breast Cancer}{section.4.1}% 94
\BOOKMARK [2][-]{subsection.4.1.2}{Expression Profiles of Synthetic Lethal Partners}{section.4.1}% 95
\BOOKMARK [3][-]{subsubsection.4.1.2.1}{Subgroup Pathway Analysis}{subsection.4.1.2}% 96
\BOOKMARK [1][-]{section.4.2}{Comparing Synthetic Lethal Gene Candidates}{chapter.4}% 97
\BOOKMARK [2][-]{subsection.4.2.1}{Primary siRNA Screen Candidates}{section.4.2}% 98
\BOOKMARK [2][-]{subsection.4.2.2}{Comparison with Correlation}{section.4.2}% 99
\BOOKMARK [2][-]{subsection.4.2.3}{Comparison with Primary Screen Viability}{section.4.2}% 100
\BOOKMARK [2][-]{subsection.4.2.4}{Comparison with Secondary siRNA Screen Validation}{section.4.2}% 101
\BOOKMARK [2][-]{subsection.4.2.5}{Comparison to Primary Screen at Pathway Level}{section.4.2}% 102
\BOOKMARK [3][-]{subsubsection.4.2.5.1}{Resampling Genes for Pathway Enrichment}{subsection.4.2.5}% 103
\BOOKMARK [2][-]{subsection.4.2.6}{Integrating Synthetic Lethal Pathways and Screens}{section.4.2}% 104
\BOOKMARK [1][-]{section.4.3}{Synthetic Lethal Pathway Metagenes}{chapter.4}% 105
\BOOKMARK [1][-]{section.4.4}{Replication in Stomach Cancer}{chapter.4}% 106
\BOOKMARK [2][-]{subsection.4.4.1}{Synthetic Lethal Genes and Pathways}{section.4.4}% 107
\BOOKMARK [2][-]{subsection.4.4.2}{Synthetic Lethal Expression Profiles}{section.4.4}% 108
\BOOKMARK [2][-]{subsection.4.4.3}{Comparison to Primary Screen}{section.4.4}% 109
\BOOKMARK [3][-]{subsubsection.4.4.3.1}{Resampling Analysis}{subsection.4.4.3}% 110
\BOOKMARK [2][-]{subsection.4.4.4}{Metagene Analysis}{section.4.4}% 111
\BOOKMARK [1][-]{section.4.5}{Discussion}{chapter.4}% 112
\BOOKMARK [2][-]{subsection.4.5.1}{Strengths of the SLIPT Methodology}{section.4.5}% 113
\BOOKMARK [2][-]{subsection.4.5.2}{Synthetic Lethal Pathways for E-cadherin}{section.4.5}% 114
\BOOKMARK [2][-]{subsection.4.5.3}{Replication and Validation}{section.4.5}% 115
\BOOKMARK [3][-]{subsubsection.4.5.3.1}{Integration with siRNA Screening}{subsection.4.5.3}% 116
\BOOKMARK [3][-]{subsubsection.4.5.3.2}{Replication across Tissues}{subsection.4.5.3}% 117
\BOOKMARK [1][-]{section.4.6}{Summary}{chapter.4}% 118
\BOOKMARK [0][-]{chapter.5}{Synthetic Lethal Pathway Structure}{}% 119
\BOOKMARK [1][-]{section.5.1}{Synthetic Lethal Genes in Reactome Pathways}{chapter.5}% 120
\BOOKMARK [2][-]{subsection.5.1.1}{The PI3K/AKT Pathway}{section.5.1}% 121
\BOOKMARK [2][-]{subsection.5.1.2}{The Extracellular Matrix}{section.5.1}% 122
\BOOKMARK [2][-]{subsection.5.1.3}{G Protein Coupled Receptors}{section.5.1}% 123
\BOOKMARK [2][-]{subsection.5.1.4}{Gene Regulation and Translation}{section.5.1}% 124
\BOOKMARK [1][-]{section.5.2}{Network Analysis of Synthetic Lethal Genes}{chapter.5}% 125
\BOOKMARK [2][-]{subsection.5.2.1}{Gene Connectivity and Vertex Degree}{section.5.2}% 126
\BOOKMARK [2][-]{subsection.5.2.2}{Gene Importance and Centrality}{section.5.2}% 127
\BOOKMARK [3][-]{subsubsection.5.2.2.1}{Information Centrality}{subsection.5.2.2}% 128
\BOOKMARK [3][-]{subsubsection.5.2.2.2}{PageRank Centrality}{subsection.5.2.2}% 129
\BOOKMARK [1][-]{section.5.3}{Relationships between Synthetic Lethal Genes}{chapter.5}% 130
\BOOKMARK [2][-]{subsection.5.3.1}{Detecting Upstream or Downstream Synthetic Lethality}{section.5.3}% 131
\BOOKMARK [2][-]{subsection.5.3.2}{Resampling for Synthetic Lethal Pathway Structure}{section.5.3}% 132
\BOOKMARK [1][-]{section.5.4}{Discussion}{chapter.5}% 133
\BOOKMARK [1][-]{section.5.5}{Summary}{chapter.5}% 134
\BOOKMARK [0][-]{chapter.6}{Simulation and Modelling of Synthetic Lethal Pathways}{}% 135
\BOOKMARK [1][-]{section.6.1}{Synthetic Lethal Detection Methods}{chapter.6}% 136
\BOOKMARK [2][-]{subsection.6.1.1}{Performance of SLIPT and 2 across Quantiles}{section.6.1}% 137
\BOOKMARK [3][-]{subsubsection.6.1.1.1}{Correlated Query Genes affects Specificity}{subsection.6.1.1}% 138
\BOOKMARK [2][-]{subsection.6.1.2}{Alternative Synthetic Lethal Detection Strategies}{section.6.1}% 139
\BOOKMARK [3][-]{subsubsection.6.1.2.1}{Correl